Comerica Securities’s Emergent Biosolutions EBS Stock Holding History

Comerica Securities’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14	Closed	-$165	–	733
2022 Q4	$165	Buy	+14	New	+$217	﹤0.01%	1496

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Comerica Securities's EBS Position: Q1 2023 in Review

Comerica Securities sold out of Emergent Biosolutions (EBS) in Q1 2023, closing a stake of 14 shares — an estimated $165 sold.

Comerica Securities first reported a position in EBS in Q4 2022 and held it in 1 quarter. The position peaked at $165 in Q4 2022. 191 funds tracked by Wall St. Rank hold EBS as of Q1 2023.

Comerica Securities reported no remaining Emergent Biosolutions position as of Q1 2023 after selling out during the quarter.
Comerica Securities sold 14 Emergent Biosolutions shares in Q1 2023, an estimated $165.
Comerica Securities first reported a position in Emergent Biosolutions in Q4 2022 and held it in 1 quarter.
Comerica Securities's Emergent Biosolutions position peaked at $165 in Q4 2022.
191 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.